Incidence of malignant neoplasms among HIV-infected persons in Scotland by Allardice, G M et al.
Short Communication
Incidence of malignant neoplasms among HIV-infected persons in
Scotland
GM Allardice*,1, DJ Hole
2, DH Brewster
3, J Boyd
3 and DJ Goldberg
4
1Department of Statistics and Modelling Science, University of Strathclyde, 7th Floor Livingstone Tower, 26 Richmond Street, Glasgow G1 1XH, UK;
2Department of Public Health, University of Glasgow, Glasgow G12 8RZ, UK;
3Information and Statistics Division, Common Services Agency, Trinity Park
House, Edinburgh EH5 3SQ, UK;
4Scottish Centre for Infection and Environmental Health, Clifton House, Clifton Place, Glasgow G3 7LN, UK
Among 2574 persons diagnosed with HIV throughout Scotland and observed over the period 1981–1996, cancer incidence
compared to the general population was 11 times higher overall; among homosexual/bisexual males, it was 21 times higher and
among injecting drug users, haemophiliacs and heterosexuals it was five times higher, mostly due to AIDS-defining neoplasms.
However, liver, lung and skin cancers (all non-AIDS-defining) were also significantly increased.
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Knowledge of cancer excess in people with HIV has largely been
based on (a) case reports or case series (b) matching population-
based cancer registries with AIDS registries or (c) following up
specific cohorts of HIV-infected individuals. Large relative risks
are reported for AIDS-defining cancers, but the possible relation-
ship between HIV and non-AIDS-defining cancers is less
conclusive. In Scotland, a high incidence of many cancers and
the existence of two high-quality, national, computerised databases
on HIV and cancer incidence afforded an opportunity to adopt a
computer linkage approach to examine the occurrence of
malignant neoplasms (both AIDS and non-AIDS defining) among
all HIV–diagnosed persons across Scotland.
MATERIALS AND METHODS
Records on Scotland’s HIV database were linked with those on the
Scottish Cancer Registry to determine the incidence of malignant
neoplasms among persons diagnosed with HIV in Scotland. The
Scottish HIV Database (Goldberg et al, 1992) holds data on all
persons who have tested HIV antibody positive and/or been
diagnosed with AIDS in Scotland since the early 1980s; data
include date of birth, initials, soundex code of surname, AIDS-
defining illness and dates of first HIV antibody positive test, AIDS
diagnosis and death. The risk category distribution of the
database’s diagnoses is relatively even: 34% injecting drug users
(IDU), 34% homosexual/bisexual males, 24% heterosexual and 8%
other risk groups. The Scottish Cancer Registry holds a range of
both patient and tumour-related information, including demo-
graphic and diagnostic details, on all cancers (ICD-9 codes 140–
208) diagnosed in Scotland since 1959.
The linkage exercise was restricted to the period 1980–1996, the
era prior to the full introduction of Highly Active Antiretroviral
Therapy (HAART) in Scotland. All malignant neoplasms identified
through the linkage process were eligible for inclusion in the
analysis, provided they were diagnosed after the HIV diagnosis or
preceded it by 2 months or less. This latter criterion allowed for the
possibility that the discovery of a malignant neoplasm may have
instigated an HIV test and subsequent HIV diagnosis. Links
between the two databases were identified using probability
linkage techniques and utilising the expertise of the Scottish
Record Linkage Group (Kendrick and Clarke, 1993).
The expected numbers of malignant neoplasms occurring
among the HIV cohort, assuming the same incidence as that for
a matched general population in Scotland, was calculated using
age-group, sex, year (for the period 1980–1996) and site-specific
data held on the Scottish Cancer Registry. The Standardised
Incidence Ratio (SIR) was defined as the ratio of the observed to
expected number of neoplasms and the confidence interval
calculated assuming that the observed number followed a Poisson
distribution.
RESULTS
The HIV Database comprised 2574 HIV-infected individuals
testing HIV antibody positive between 1981 and 1996, of whom
1955 were male and 619 female. Follow-up to death or 31st
December 1996 provided 11677 and 4236 person-years of follow-
up for males and females, respectively. The cohort’s median age at
HIV diagnosis was 28 years and comprised 58 children (aged 14
years or less at HIV diagnosis). The linkage process identified 162
malignant neoplasms (two occurring in children). The incidence of
malignancy among the HIV-infected population was 11 times that
of the general population, SIR¼10.8 (95% CI 9.2, 12.6). The
incidence was 21 times higher among homosexual/bisexual males
and five to six times higher among the IDU, haemophiliac and
heterosexual risk groups (Table 1). Of the 138 AIDS-defining
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ymalignant neoplasms, 82 were non-Hodgkin’s lymphomas, 55
Kaposi’s sarcomas and one was an invasive cervical cancer. The
SIRs for the 138 AIDS-defining and 24 non-AIDS-defining
neoplasms were 100.0 (95% CI 84.1, 118.1) and 1.8 (95% CI 1.1,
2.6), respectively. Most of the non-AIDS-defining SIRs were of the
order 1–4, with the exception of those for liver and bone cancers.
The SIRs for liver, lung and skin cancers were statistically
significant.
DISCUSSION
This study confirmed the large expected excess risks of non-
Hodgkin’s lymphoma and Kaposi’s sarcoma among HIV-infected
persons; the latter finding is consistent with the previous
observation of an increased incidence of Kaposi’s sarcoma during
the mid 1980s in Scotland (Brewster et al, 1999). Although invasive
cervical cancer is an AIDS indicator disease, only one case was
diagnosed; its SIR was 1.7 (0.04, 9.26), a considerably lower ratio
than the statistically significant ones associated with cancers of the
liver and lungs.
An important finding was the SIR of 1.8 (95% CI 1.1, 2.6) for the
non-AIDS-defining malignant neoplasms. Other studies identified
a 2-3 fold risk of non-AIDS-defining malignant neoplasms among
AIDS patients and an excess of liver cancer (Serraino et al, 2000),
lung cancer (Grulich et al, 1999; Frisch et al, 2001) and skin
cancers (Cooksley et al, 1999) among HIV-infected persons. Unlike
several other studies, we did not find a significant excess of
Hodgkin’s disease (Cooksley et al, 1999; Grulich et al, 1999;
Serraino et al, 2000; Frisch et al, 2001).
The possibility that some of the non-AIDS-defining neoplasms
were extranodal lymphomas, or Kaposi’s sarcomas that had been
misdiagnosed or miscoded as other types of cancer, cannot be
excluded. Most of the cancers in question, however, were recorded
as being microscopically verified and the reliability of diagnostic
coding for the Scottish Cancer Registry is high (Brewster et al,
1994).
In this study, it was impossible to associate cancers with
immunodeficiency, lifestyle, deprivation or coinfection with
another virus. Accordingly, the excess of lung cancer may be due
to high rates of smoking among HIV-infected gay men and the
excess of liver cancer may be related to HIV/hepatitis coinfection,
especially among IDUs. In Scotland, the incidence of many cancers
varies by deprivation category; however, deprivation scores were
not available for the HIV cohort.
The study method is subject to some potential biases. Persons
belonging to the HIV cohort might have been subject to closer
clinical scrutiny than those in the general population; this could
have led to earlier diagnoses in the former. In contrast, emigration
of any HIV-infected persons will have tended to underestimate
cancer risk due to an overestimation of person-years at risk and
the failure to ascertain and register any subsequent cancers arising
in emigrants.
Since the aim of the investigation was to determine the natural
history of neoplasia incidence among a national HIV cohort, the
linkage was not extended beyond 1996, the time when Highly
Active Anti-Retroviral Therapy (HAART) became widely adminis-
tered in Scotland. The investigators plan to repeat the linkage to
determine how much the incidence of neoplasia has changed
during the era of HAART.
Table 1 Observed malignant neoplasms by HIV Risk Group, AIDS-defining status, site and morphology: SIR and 95% CI (SIR)
HIV risk group AIDS/non-AIDS defining Cancer site Morphology N SIR 95% CI SIR
All risks AIDS and non-AIDS All All 162 10.8 9.2, 12.6
Heterosexual AIDS and non-AIDS All All 14 5.9 3.2, 9.9
Homo/bisexual AIDS and non-AIDS All All 102 21.4 17.4, 26.1
IDU AIDS and non-AIDS All All 35 5.5 3.8, 7.6
Haemophiliac AIDS and non-AIDS All All 5 6.1 2.0, 14.2
Other/mixed AIDS and non-AIDS All All 6 9.0 3.3, 19.6
All risks AIDS All All 138 100 84.1, 118.1
All risks AIDS Skin (45), Connective and
soft tissue (5)
Head and Neck (4)
Lung (1)
Kaposi’s sarcoma 55 2750 2067, 3583
All risks AIDS Not available Non-Hodgkin’s lymphoma 82 108 85.6, 134.4
All risks AIDS Cervical Squamous cell carcinoma 1 1.7 0.04, 9.26
All risks Non-AIDS All All 24 1.8 1.1, 2.6
All risks Non-AIDS Skin Squamous cell carcinoma (3),
Basal cell carcinoma (1),
Unspecified (2)
6 2.8 1.04, 6.2




5 4.1 1.3, 9.5
All risks Non-AIDS Liver Hepatocellular carcinoma 2 22.0 2.7, 80.2
All risks Non-AIDS Bladder Transitional cell carcinoma (1),
Papillary cell carcinoma (1)
2 4.2 0.5, 15.0
All risks Non-AIDS Brain and CNS Astrocytoma 2 3.3 0.4, 12.0
All risks Non-AIDS Not available Hodgkin’s disease 2 3.6 0.4, 13.1
All risks Non-AIDS Bone Ewing’s sarcoma 1 9.1 0.23, 50.5
All risks Non-AIDS Head and neck Unspecified 1 1.6 0.04, 8.8
All risks Non-AIDS Leukaemias Acute myeloid leukaemia 1 2.2 0.06, 12.4
All risks Non-AIDS Stomach Unspecified 1 2.9 0.07, 15.9
All risks Non-AIDS Testis Seminoma 1 0.7 0.02, 3.75
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